Rocket Pharmaceuticals Inc (NASDAQ:RCKT) shares, rose in value on Thursday, March 06, with the stock price down by -2.39% to the previous day’s close as strong demand from buyers drove the stock to $8.99.
Actively observing the price movement in the last trading, the stock closed the session at $9.21. Referring to stock’s 52-week performance, its high was $28.73, and the low was $8.25. On the whole, RCKT has fluctuated by -18.86% over the past month.
With the market capitalization of Rocket Pharmaceuticals Inc currently standing at about $958.60 million, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 800k.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that RCKT’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of RCKT currently trading nearly -9.16% and -15.99% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 36.55, while the 7-day volatility ratio is showing 7.14% which for the 30-day chart, stands at 5.75%. Furthermore, Rocket Pharmaceuticals Inc (RCKT)’s beta value is 0.87, and its average true range (ATR) is 0.60.
A comparison of Rocket Pharmaceuticals Inc (RCKT) with its peers suggests the former has fared considerably weaker in the market. RCKT showed an intraday change of -2.39% in last session, and over the past year, it shrunk by -68.69%%.
Data on historical trading for Rocket Pharmaceuticals Inc (NASDAQ:RCKT) indicates that the trading volumes over the past 3 months, they’ve averaged 1.54 million. According to company’s latest data on outstanding shares, there are 106.45 million shares outstanding.
Nearly 7.18% of Rocket Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 101.12% of the company’s shares. The stock has fallen by -28.48% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RCKT stock heading into the next quarter.
